Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Conference data puts UCB's neurology pipeline in focus

UCB (ENXTBR:UCB) is in the spotlight after presenting 21 neurology abstracts at the American Academy of Neurology 2026 meeting, including new real world data on developmental and epileptic encephalopathies and generalized myasthenia gravis.

See our latest analysis for UCB.

Despite a 1-day share price return of 1.32% to €246.3 after the neurology data updates, UCB's recent 7-day and 90-day share price returns of 4.79% and 4.31% declines contrast with a strong 1-year total shareholder return of 68.26% and a 5-year total shareholder return of 233.74%. This suggests that longer term momentum has been much stronger than the shorter term pullback.

If this neurology story has your attention, it could be worth scanning for other specialist healthcare names using our focused screener for 127 healthcare AI stocks

With UCB trading at €246.3, sitting at a 16% discount to the average analyst price target and a 58% gap to one intrinsic value estimate, the key question is whether there is still an entry point here or if the market is already pricing in future growth.

Most Popular Narrative: 13.5% Undervalued

UCB's most followed narrative places fair value at €284.65, above the last close of €246.3. This frames the neurology story within a broader, earnings-led thesis.

UCB's deep and advancing innovation pipeline, along with its focus on differentiated products in neurology and immunology, supports the ability to launch multiple new indications, address rare/orphan diseases, and leverage advances in personalized medicine, all of which underpin sustained long-term revenue growth and margin expansion.

Read the complete narrative.

This raises the question of what sits behind that price gap. The narrative leans on double digit top line growth, rising margins, and a future earnings base that looks very different to today.

Result: Fair Value of €284.65 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that thesis still hinges on avoiding sharp U.S. pricing pressure on key drugs and on managing patent expiries that could eat into UCB's current earnings base.

Find out about the key risks to this UCB narrative.

Another View: Earnings Multiple Sends A Different Signal

While the SWS DCF model points to a fair value of €587.42 and labels UCB as undervalued at €246.3, the P/E of 30.1x looks expensive compared with the European pharmaceuticals average of 21.1x. The fair ratio sits at 32x. Is the real tension here between growth expectations and what you are willing to pay for them?